News

CAMBRIDGE, Mass., May 31st, 2024  – Rgenta Therapeutics, a biotechnology company pioneering the development of a new class of oral small molecules for therapeutic RNA modification for oncology and CNS disorders, today announced the presentation of preclinical data at ASCO 2024 from its lead program, RGT-61159, which is being developed for the potential treatment of adenoid cystic carcinoma (ACC), colorectal cancer (CRC) and other solid tumors as well as acute myeloid leukemia (AML).

Read more …

CAMBRIDGE, Mass., Feb 26th, 2024 – Rgenta Therapeutics (“Rgenta” or the “Company”) is developing a pipeline of oral, small-molecule RNA-targeting medicines with lead programs in IND enabling stage targeting root causes of oncology and neurological disorders.

Rgenta will participate the TD Cowen 44th Annual Health Care Conference on March 4 th 2024 and host one-on-one meetings with investors. Please contact your TD Cowen representative if interested in scheduling a meeting with the Rgenta management team.

Read more …

CAMBRIDGE, Mass., February 21, 2024 /PRNewswire/ — Rgenta Therapeutics today announced it will participate at the 19th Annual Huntington’s Disease Therapeutics Conference being held February 26-29, 2024, in Palm Springs, California.

Read more …

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ — Rgenta Therapeutics today announced that it was selected by The Leukemia & Lymphoma Society (LLS) as a new Therapy Acceleration Program® (TAP) portfolio company, and provided with strategic funding to support preclinical and clinical advancement of the Company’s therapeutics in hematologic malignancies utilizing its RNA-targeting small molecule platform to target MYB, an oncogenic transcription factor.

Read more …

CAMBRIDGE, Mass.June 21, 2023 /PRNewswire/ — Rgenta Therapeutics today announced the formation of a Repeat Expansion Diseases (REDs) Focused Scientific Advisory Board (REDs SAB). REDs SAB is an esteemed group of preclinical and clinical experts who contribute to basic and translational research on the mechanisms and treatments for repeat expansion diseases.

Read more …

CAMBRIDGE, Mass.Nov. 29, 2022 /PRNewswire/ — Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors including Korean Investment Partners, Delos Capital. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets. Read more …

Cambridge, MA biotech Rgenta Therapeutics has secured $52 million in a Series A to take oral small molecules into the clinic.

The 20-person biotech, which is already allied with Lundbeck, looks to ink more pharma partnerships within its core areas of oncology and neuroscience rare diseases, as well as in other disease areas the startup thinks the RNA-targeting platform can go, CSO Travis Wager told Endpoints News ahead of the Tuesday morning news. Read more …

CAMBRIDGE, Mass., Aug. 4, 2021 /PRNewswire/ — Rgenta Therapeutics, Inc., announced today a strategic R&D collaboration with H. Lundbeck A/S aimed at the discovery of small molecules targeting RNA regulation and splicing of disease-causing genes for neurological disorders. Read more…

After selling off a discarded Alzheimer’s disease drug last month, Lundbeck is bulking up its neurological R&D through a $10 million pact with the relatively unknown small biotech Rgenta Therapeutics. Read more …..

CAMBRIDGE, Mass., May 25, 2021 — Rgenta Therapeutics announced today that it closed an $18 million seed extension round and welcomed Lilly Asia Venture (LAV) and Vivo Capital as new investors to the syndicate. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets. Read more…..

 

CAMBRIDGE, Mass.May 25, 2021 /PRNewswire/ — Rgenta Therapeutics announced today that it closed an $18 million seed extension round and welcomed Lilly Asia Venture (LAV) and Vivo Capital as new investors to the syndicate. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets. Read more …

Paris (France) and Cambridge (U.S.), May 5, 2020 – Servier has awarded the 2020 Servier Golden Ticket at LabCentral to Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets. Read more…

CAMBRIDGE, Mass., April 2, 2020 /PRNewswire/ — Rgenta Therapeutics, a new biotechnology company focusing on developing RNA-targeting medicines for historically undruggable disease-relevant targets, announced today that it closed a $20 Million seed investment, co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China. Rounding out the series seed syndicate are two additional investors, Kaitai Capital and Legend Star Fund. The company has assembled a world-class team of small-molecule drug developers and an exceptional Scientific Advisory Board in the fields of genomics and RNA biology. Read more…..